Matinas BioPharma Holdings Inc. appointed Patrick LePore as vice chairman of the board.
LePore served as the CEO, chairman and president of Par Pharmaceuticals Inc. from 2006 to 2012.
Matinas Biopharma said in a Sept. 6 news release that Lepore oversaw the sale of Par Pharmaceuticals to Texas Pacific Group for $2 billion in November 2012 and was appointed as the chairman. He oversaw the new company's $8 billion sale to Endo International PLC in 2015.
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.